Radar · Neurology in United States
Best Neurology Companies in United States
The 1624 best Neurology companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Assertio.
By Riya SenguptaFinancials
1624companies tracked
$38.7Bdisclosed funding
6unicorns
894have raised
Ranking the best Neurology companies across the United States by disclosed equity funding and recent momentum, this directory tracks 1,624 ventures carrying $38.7B in total disclosed capital. Six have crossed unicorn territory. Neuralink leads by sheer funding weight at $680M, with Cognito Therapeutics ($227M) and Achieve Life Sciences ($264M) not far behind. The investor roster tells you something too: HHS, NIH, and the Michael J. Fox Foundation aren't chasing hype, they're writing checks into durable clinical problems. The [global neurology market sits at roughly $112.5B in 2025, forecast to reach $180.2B by 2032 at a 6.9% CAGR](https://www.biospace.com/neurology-market-expected-to-witness-sustained-growth), driven by an aging population and accelerating neuroimaging research.
The revenue picture is what I find most grounding. Across 29 validated filers, the combined pool hits $6.3B, with median revenue at $50M and median growth at 19% YoY. Biogen anchors the top at $2.5B, though its 2% growth is modest compared to Alkermes at $393M growing 28%. So who's actually printing profit? Biogen's net income runs 26x the sector median of $12M, with Jazz Pharmaceuticals and Alkermes both posting outsized returns as well. Hot themes right now include cognitive aging studies and stress-induced neuroinflammation. The earned revenue here is real, and it's growing.
Sources & further reading
- MVT: Building the promise of Heal in India
- Neurobiology of Eating Disorders: Clinical Implications
- Is India Prepared to be a Global Medical Tourism Center?
FLIAR INTELLIGENCE · NEUROLOGY × UNITED STATES
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
74%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
878kcombined LinkedIn audience
59%of audience held by top 3
10companies hiring publicly (12 mo)
Ranked: Best Neurology companies in United States
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Neuralink 🦄 Provider of implantable brain-computer interfaces 78Funding top 15%Patents top 25%Moat top 25%Innovation top 27% All 10 signals ▾Fundingtop 15% Patentstop 25% Moattop 25% Innovationtop 27% Talenttop 28% Markettop 33% Growthtop 42% Techtop 44% Globalbottom 39% Newsbottom 24% Funding: Raised $680M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) Patents: 97 patents matched (strict assignee match) · 62 filings since 2022 vs 35 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $680M | 1 mo ago | Series E | 197 | Dongjin Seo Co-Founder | — | 97 patents High‑density, biocompatible neural interface hardware and real‑time spike processing | 1 launch |
| 2 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | Series D | 159 | Shankar Ramaswamy Co-Founder & CEO | 5 signals Funding · Capital raise · Leadership | — | — |
| 3 | Enveda 🦄 AI-based platform to decipher the chemistry of nature and develop new medicines 72Funding top 12%Moat top 32%Growth top 35%Market top 44% All 8 signals ▾Fundingtop 12% Moattop 32% Growthtop 35% Markettop 44% AItop 45% Talentbottom 49% Globalbottom 48% Techbottom 46% Funding: Raised $505M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Moat: Unicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 72/100 | $505M | 9 mo ago | Series D | — | Viswa Colluru Founder & CEO | — | — | — |
| 4 | Saluda Medical Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment 62Funding top 14%Moat top 31%News top 39%Growth top 42% All 8 signals ▾Fundingtop 14% Moattop 31% Newstop 39% Growthtop 42% Markettop 44% Techtop 45% Talentbottom 49% Globalbottom 43% Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 62/100 | $400M | 7 mo ago | Public | 327 | Jim Schuermann CEO | 3 signals ▲50% IPO | — | 1 launch |
| 5 | Neurona Therapeutics Developer of cell-based therapies to treat intractable neurological diseases 55Funding top 22%Moat top 31%Growth top 32%AI top 45% All 8 signals ▾Fundingtop 22% Moattop 31% Growthtop 32% AItop 45% Talentbottom 49% Marketbottom 43% Globalbottom 39% Techbottom 30% Funding: Raised $316M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $316M | 14 mo ago | Acquired | 67 67 → 116 (+73%) · sector median +71% | Cory Nicholas CEO | — | — | 1 award |
| 6 | MapLight Developer of therapeutic for central nervous system disorders 50Funding top 13%Growth top 28%Talent top 38%Moat top 39% All 7 signals ▾Fundingtop 13% Growthtop 28% Talenttop 38% Moattop 39% Globalbottom 39% Marketbottom 33% Techbottom 32% Funding: Raised $305M across 7 rounds · 7 rounds over 6 yrs (1.2/yr) Growth: Headcount 20 → 27 (+35%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $305M | 11 mo ago | Public | 27 | Chris Kroeger Founder & CEO | — | — | — |
| 7 | Achieve Life Sciences Developer of plant-based alkaloid for treating smoking cessation 37Funding top 11%News top 42%Moat top 48%Tech top 50% All 7 signals ▾Fundingtop 11% Newstop 42% Moattop 48% Techtop 50% Globalbottom 44% Marketbottom 40% Growthbottom 34% Funding: Raised $264M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) News: 9 BI events in 12 mo (of 54 tracked, 8 types) · -53% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $264M | 1 mo ago | Public | 25 25 → 40 (+60%) · sector median +71% | — | 9 signals ▼53% Leadership · Earnings | — | — |
| 8 | Merge Labs Developer of brain-computer interfaces to maximize human ability, agency, experience 48Talent top 28%Funding top 31%AI top 45%Patents top 49% All 8 signals ▾Talenttop 28% Fundingtop 31% AItop 45% Patentstop 49% Innovationbottom 49% Techbottom 45% Globalbottom 42% Marketbottom 31% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $250M | 5 mo ago | Seed | — | Sumner Norman Co-Founder | — | 40 patents Real-time multi-user AR collaboration and interactive media streaming platforms | — |
| 9 | Biohaven Developer of radiopharmaceuticals for the treatment of neurological and neuropsychiatric diseases 72Funding top 19%News top 27%Growth top 30%Market top 40% All 8 signals ▾Fundingtop 19% Newstop 27% Growthtop 30% Markettop 40% Techtop 40% Fin. healthtop 43% Moatbottom 41% Globalbottom 32% Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 13 BI events in 12 mo (of 43 tracked, 9 types) · +86% YoY rank vs industry peers · Fliar Intelligence Index 72/100 | $250M | 13 mo ago | Public | 202 | — | 13 signals ▲86% Earnings · IPO · Regulatory | — | 1 internship · 1 expansion |
| 10 | Minerva Neurosciences Innovating central nervous system disorder treatments with clinical expertise and patient focus 50Patents top 22%Funding top 26%Innovation top 27%Fin. health bottom 48% All 9 signals ▾Patentstop 22% Fundingtop 26% Innovationtop 27% Fin. healthbottom 48% Moatbottom 48% Globalbottom 44% Techbottom 40% Marketbottom 38% Newsbottom 38% Patents: 216 patents matched (strict assignee match) · 111 filings since 2022 vs 89 in 2017-21 Funding: Raised $247M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $247M | 7 mo ago | Acquired | 10 | — | — | 216 patents Novel CNS drug molecules and gastro-resistant oral formulations for psychiatric and metabolic disorders | — |
| 11 | Cognito Therapeutics Developer of a medical device for the treatment of Alzheimer's disease 60Talent top 22%Funding top 23%Growth top 35%Moat top 42% All 8 signals ▾Talenttop 22% Fundingtop 23% Growthtop 35% Moattop 42% Techtop 50% Marketbottom 43% Globalbottom 37% Newsbottom 21% Talent: Analyst team rating 5/5 · 3 named leaders on record Funding: Raised $227M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $227M | 3 mo ago | Series C | 42 | Ed Boyden Co-Founder | — | — | — |
| 12 | Aspen Neuroscience Provider of genomic-based personalised pluripotent stem cell therapy 64Funding top 17%Patents top 23%Moat top 28%Innovation top 33% All 10 signals ▾Fundingtop 17% Patentstop 23% Moattop 28% Innovationtop 33% Growthtop 35% Newstop 45% Marketbottom 49% Talentbottom 49% Techbottom 46% Globalbottom 45% Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $224M | 6 mo ago | Series C | 94 | Damien Mcdevitt President | — | 57 patents Patents concentrated in computing, sensing & instrumentation | — |
| 13 | Apnimed Developer of small molecule based therapeutics for the treatment of obstructive sleep apnea 37Funding top 14%Growth top 28%Talent top 28%Moat top 35% All 12 signals ▾Fundingtop 14% Growthtop 28% Talenttop 28% Moattop 35% Producttop 40% Techbottom 49% Globalbottom 37% Patentsbottom 34% Marketbottom 32% Innovationbottom 21% Newsbottom 18% Customersbottom 3% Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $208M | 2 mo ago | Series C | 13 | Andrew Wellman Co-Founder | — | 2 patents Pharmaceutical solid‑form optimization and repurposed drug therapy for sleep‑apnea treatment | 1 job opening · 1 award |
| 14 | LEXEO Therapeutics Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases 29Funding top 19%News top 43%Growth top 47%Tech bottom 49% All 9 signals ▾Fundingtop 19% Newstop 43% Growthtop 47% Techbottom 49% Talentbottom 40% Globalbottom 39% Marketbottom 31% Moatbottom 31% Fin. healthbottom 29% Funding: Raised $185M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) News: 7 BI events in 12 mo (of 27 tracked, 4 types) · -36% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $185M | 7 mo ago | Public | 58 58 → 97 (+67%) · sector median +71% | Nolan Townsend CEO | 7 signals ▼36% Earnings · Funding · Leadership | — | 1 launch |
| 15 | Monteris Minimally invasive robotic laser thermotherapy 55Funding top 15%Moat top 31%Talent top 38%Market top 43% All 8 signals ▾Fundingtop 15% Moattop 31% Talenttop 38% Markettop 43% Growthtop 48% Newsbottom 42% Techbottom 38% Globalbottom 37% Funding: Raised $174M across 20 rounds · 20 rounds over 18 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $174M | 3 mo ago | Series E | 100 100 → 128 (+28%) · sector median +71% | Richard Tyc Co-Founder & SVP Science & Technology | — | — | — |
| 16 | Precision Neuroscience Developed of brain-computer interface tool for medical treatment and drug development 50Funding top 18%Moat top 31%Talent top 38%Tech top 39% All 9 signals ▾Fundingtop 18% Moattop 31% Talenttop 38% Techtop 39% AItop 45% Growthbottom 40% Globalbottom 37% Marketbottom 34% Newsbottom 18% Funding: Raised $174M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $174M | 7 mo ago | Series C | 22 | Benjamin Rapoport Co-Founder & CSO | — | — | 1 job opening · 2 launchs · 1 award |
| 17 | Cala Health Developer of a wearable non-invasive neuromodulation device 60Funding top 17%Product top 21%Innovation top 22%Patents top 26% All 11 signals ▾Fundingtop 17% Producttop 21% Innovationtop 22% Patentstop 26% Moattop 26% Talenttop 38% Techtop 46% Growthbottom 44% Marketbottom 43% Globalbottom 42% Newsbottom 21% Funding: Raised $157M across 7 rounds · 7 rounds over 13 yrs (0.5/yr) Product: 6 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 60/100 | $157M | 1 mo ago | Series D | 50 50 → 122 (+144%) · sector median +71% | Kate Rosenbluth Founder and Co-President | — | 243 patents Wearable peripheral nerve stimulation devices for tremor, movement and musculoskeletal disorder therapy | 1 award |
| 18 | Synchron Developer of implantable bioelectronics for the treatment of neurological conditions 48Funding top 17%News top 30%Talent top 38%Growth top 47% All 8 signals ▾Fundingtop 17% Newstop 30% Talenttop 38% Growthtop 47% Moattop 48% Marketbottom 46% Globalbottom 39% Techbottom 35% Funding: Raised $145M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) News: 3 BI events in 12 mo (of 14 tracked, 7 types) · Top themes: Funding, Capital raise rank vs industry peers · Fliar Intelligence Index 48/100 | $145M | 7 mo ago | Series D | 53 53 → 130 (+145%) · sector median +71% | Rahul Sharma Co-Founder | 3 signals Funding · Capital raise | — | 2 job openings |
| 19 | Alto Neuroscience AI-driven drug discovery platform for neurological diseases based on patients biomarkers 72Funding top 12%Patents top 25%Growth top 30%Moat top 32% All 11 signals ▾Fundingtop 12% Patentstop 25% Growthtop 30% Moattop 32% Innovationtop 33% Techtop 45% AItop 45% Globalbottom 49% Talentbottom 49% Newsbottom 44% Marketbottom 40% Funding: Raised $145M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Patents: 57 patents matched (strict assignee match) · 57 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $145M | 3 mo ago | Public | 34 | Amit Etkin Founder & CEO | 3 signals ▼25% Earnings | 57 patents Neuropsychiatric therapeutics: combinatorial dopaminergic/serotonergic drugs and EEG‑guided patient selection | 1 award |
| 20 | QurAlis Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS) 64Funding top 20%Patents top 23%Innovation top 25%Growth top 26% All 10 signals ▾Fundingtop 20% Patentstop 23% Innovationtop 25% Growthtop 26% Moattop 32% Talenttop 41% Techbottom 43% Globalbottom 42% Marketbottom 36% Newsbottom 22% Funding: Raised $144M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Patents: 69 patents matched (strict assignee match) · 62 filings since 2022 vs 7 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 9 mo ago | Series B | 38 38 → 87 (+129%) · sector median +71% | Kasper Roet Founder & CEO | — | 69 patents Antisense oligonucleotide therapeutics targeting UNC13A for neurological disease treatment | — |
| 21 | Synaptogenix Developer of regenerative therapeutics for neurodegenerative diseases and developmental disorders 40Funding top 16%Patents top 30%Innovation top 31%Moat top 45% All 8 signals ▾Fundingtop 16% Patentstop 30% Innovationtop 31% Moattop 45% Talentbottom 49% Globalbottom 37% Newsbottom 20% Marketbottom 19% Funding: Raised $140M across 12 rounds · 12 rounds over 5 yrs (2.4/yr) Patents: 36 patents matched (strict assignee match) · 34 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $140M | 12 mo ago | Public | 5 | Alan Tuchman CEO | — | 36 patents PKC-activating compounds for treating neurodegenerative and nerve‑damage disorders | — |
| 22 | Route 92 Medical Developer of next-generation products for neurointerventional procedures 69Funding top 14%Innovation top 18%Patents top 21%Moat top 29% All 10 signals ▾Fundingtop 14% Innovationtop 18% Patentstop 21% Moattop 29% Growthtop 32% Techtop 50% Talentbottom 49% Marketbottom 45% Newsbottom 41% Globalbottom 40% Funding: Raised $138M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) Innovation: 223 patents (top 12% of patent-holders) · 137 filings since 2022 vs 82 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $138M | 5 mo ago | Series F | 51 | Tony Chou Founder & CEO | — | 223 patents Neurovascular aspiration catheters for minimally invasive stroke thrombectomy | — |
| 23 | LB Pharmaceuticals Developer of small molecule based therapeutics for schizophrenia 67Moat top 21%Growth top 23%Patents top 25%News top 27% All 10 signals ▾Moattop 21% Growthtop 23% Patentstop 25% Newstop 27% Fundingtop 30% Innovationtop 34% Talenttop 41% Marketbottom 44% Globalbottom 43% Partnersbottom 35% Moat: Editorial + unicorn rating 7/10 · IP moat: 437 patents Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 67/100 | $130M | 4 mo ago | Public | — | Zachary Prensky Founder & CEO | 17 signals ▲467% IPO · Leadership · Earnings | 437 patents Small-molecule immunomodulators targeting CXCR4/CXCR2, BTK, complement, and IL-6 pathways | — |
| 24 | Slate Medicines Developer of therapeutics for the treatment of migraine and other headache disorders 53Funding top 20%Talent bottom 49%Global bottom 48% All 3 signals ▾Fundingtop 20% Talentbottom 49% Globalbottom 48% Funding: Raised $130M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 53/100 | $130M | 3 mo ago | Series A | — | Neil Buckley Co-Founder & CEO | — | — | — |
| 25 | Conformal Medical Innovating stroke prevention with minimally invasive Left Atrial Appendage Occlusion 50Funding top 20%Talent top 22%Growth top 26%Moat top 31% All 9 signals ▾Fundingtop 20% Talenttop 22% Growthtop 26% Moattop 31% Producttop 36% Newsbottom 45% Marketbottom 33% Globalbottom 32% Techbottom 24% Funding: Raised $129M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Talent: Analyst team rating 5/5 · 3 named leaders on record rank vs industry peers · Fliar Intelligence Index 50/100 | $129M | 10 mo ago | Series D | 29 29 → 57 (+97%) · sector median +71% | Aaron Kaplan Founder and Chairman | — | — | — |
| 26 | ElectroCore Developer of non-invasive vagus nerve stimulation devices 62Funding top 20%Patents top 20%Product top 24%Innovation top 26% All 12 signals ▾Fundingtop 20% Patentstop 20% Producttop 24% Innovationtop 26% Techtop 42% Talenttop 42% Moattop 43% Fin. healthtop 47% Marketbottom 49% Globalbottom 49% Growthbottom 47% Newsbottom 41% Funding: Raised $121M across 13 rounds · 13 rounds over 14 yrs (0.9/yr) Patents: 518 patents matched (strict assignee match) · 124 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $121M | 8 mo ago | Public | 58 58 → 98 (+69%) · sector median +71% | JP Errico Founder | 3 signals ▼90% Leadership · Earnings | 518 patents Patents concentrated in health & consumer products | — |
| 27 | Quoin Pharmaceuticals Developer of small molecule-based therapeutics for the treatment of CNS and dermatology diseases 45News top 22%Growth top 25%Funding top 29%Talent top 33% All 7 signals ▾Newstop 22% Growthtop 25% Fundingtop 29% Talenttop 33% Techtop 44% Globalbottom 32% Marketbottom 16% News: 9 BI events in 12 mo (of 45 tracked, 7 types) · +125% YoY Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 45/100 | $106M | 8 mo ago | Public | 4 | Michael Myers Co-Founder Quoin Pharmaceuticals | 9 signals ▲125% Earnings · Leadership · Announcements | — | 1 launch |
| 28 | Solid Biosciences Developer of gene therapy platform for Duchenne muscular dystrophy 53Patents top 20%Funding top 24%Innovation top 31%Tech top 33% All 10 signals ▾Patentstop 20% Fundingtop 24% Innovationtop 31% Techtop 33% Moattop 38% Newstop 48% Marketbottom 49% Growthbottom 44% Globalbottom 42% Fin. healthbottom 32% Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $92M | 3 mo ago | Public | 101 | — | 4 signals ▼33% Earnings · Funding · Leadership | 60 patents AAV vector manufacturing and formulation for cardiac gene therapies | — |
| 29 | Octave Bioscience Provider of AI-based molecular diagnostic tools for neurodegenrative diseases 69Funding top 20%Innovation top 32%Growth top 35%Product top 35% All 11 signals ▾Fundingtop 20% Innovationtop 32% Growthtop 35% Producttop 35% Talenttop 38% Moattop 39% AItop 45% Techtop 48% Marketbottom 43% Newsbottom 42% Globalbottom 38% Funding: Raised $88.0M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) Innovation: 2 product lines · Deep-tech classification: Tech Hardware rank vs industry peers · Fliar Intelligence Index 69/100 | $88M | 9 mo ago | Series C | 90 | William Hagstrom Co-Founder & CEO | — | — | 1 launch |
| 30 | Leal Therapeutics Developer of therapeutics to treat neurological diseases 32Funding top 21%Moat top 42%Talent bottom 49%Market bottom 36% All 5 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Marketbottom 36% Globalbottom 29% Funding: Raised $84.0M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 32/100 | $84M | 9 mo ago | Series A | 25 | Asa Abeliovich Founder & CEO | — | — | — |
| 31 | Gilgamesh Developer of drugs for neuropsychiatric conditions 62Growth top 15%Funding top 17%Talent top 23%News top 28% All 9 signals ▾Growthtop 15% Fundingtop 17% Talenttop 23% Newstop 28% Moattop 39% AItop 45% Techbottom 40% Globalbottom 39% Marketbottom 21% Growth: Fresh capital in last 24 mo Funding: Raised $83.1M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $83M | 2 mo ago | Series B | 2 | Jonathon Sporn Co-Founder & CEO | 5 signals ▲400% M&A | — | — |
| 32 | Emboline Developer of an aortic embolic protection device 48Funding top 22%Moat top 26%Innovation top 28%Patents top 29% All 9 signals ▾Fundingtop 22% Moattop 26% Innovationtop 28% Patentstop 29% Talenttop 38% Techbottom 44% Newsbottom 42% Globalbottom 40% Marketbottom 28% Funding: Raised $81.9M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 112 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $82M | 3 mo ago | Series D | 13 13 → 23 (+77%) · sector median +71% | Amir Belson Founder & CTO | — | 112 patents Embolic protection and delivery devices for cardiovascular catheter procedures | — |
| 33 | Latus Developer of gene therapy medicines for neurological diseases 35Funding top 26%Moat top 31%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 26% Moattop 31% Talentbottom 49% Marketbottom 40% Globalbottom 36% Funding: Raised $54.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 1 mo ago | Series A | — | P Ghoroghchian CEO | — | — | — |
| 34 | ReviR Therapeutics Developer of RNA-based therapeutics for multiple diseases 35Funding top 26%AI top 45%Moat top 47%Talent bottom 49% All 8 signals ▾Fundingtop 26% AItop 45% Moattop 47% Talentbottom 49% Marketbottom 36% Globalbottom 36% Techbottom 31% Newsbottom 18% Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 1 mo ago | Series A | 29 | Yang Li Co-Founder | — | — | 1 partnership |
| 35 | Myrtelle Developer of gene therapies for the treatment of neurological diseases 35Funding top 31%Growth top 35%Moat top 45%Patents top 49% All 9 signals ▾Fundingtop 31% Growthtop 35% Moattop 45% Patentstop 49% Talentbottom 49% Innovationbottom 47% Techbottom 41% Globalbottom 37% Marketbottom 22% Funding: Raised $44.1M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $44M | 6 mo ago | Series C | 12 12 → 11 (-8%) · sector median +71% | Mark Pykett CEO | — | 4 patents Therapeutic biotech targeting myelin repair and neurodegenerative disease treatment | — |
| 36 | CraniUS A medical technology company developing drug delivery systems to treat brain diseases and disorders 64Patents top 23%Innovation top 28%Funding top 31%Moat top 34% All 7 signals ▾Patentstop 23% Innovationtop 28% Fundingtop 31% Moattop 34% Talenttop 38% Globaltop 48% Marketbottom 49% Patents: 47 patents matched (strict assignee match) · 47 filings since 2022 vs 0 in 2017-21 Innovation: 47 patents (top 32% of patent-holders) · 47 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $42M | 4 mo ago | Series B | — | Chad Gordon Founder & CMO | — | 47 patents Implantable medical devices with flexible catheters, drug delivery, and wireless power management | — |
| 37 | PAQ Developer of small molecule therapeutics for neurodegenerative disease 24Funding top 27%Talent top 28%Moat top 39%News top 46% All 8 signals ▾Fundingtop 27% Talenttop 28% Moattop 39% Newstop 46% Patentsbottom 41% Globalbottom 37% Innovationbottom 33% Marketbottom 24% Funding: Raised $34.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 24/100 | $34M | 4 mo ago | Series B | 6 | Huaixiang Hao Co-Founder | — | 10 patents Airtight, child‑resistant, compartmentalized packaging for tobacco products | — |
| 38 | XCath Developer of endovascular robotics and steerable guidewires 45Innovation top 23%Patents top 26%Funding top 28%Moat top 28% All 7 signals ▾Innovationtop 23% Patentstop 26% Fundingtop 28% Moattop 28% Talentbottom 49% Globalbottom 40% Marketbottom 24% Innovation: 128 patents (top 15% of patent-holders) · 72 filings since 2022 vs 56 in 2017-21 Patents: 128 patents matched (strict assignee match) · 72 filings since 2022 vs 56 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $30M | 3 mo ago | Series C | 10 | Eduardo Fonseca CEO | — | 128 patents Patents concentrated in health & consumer products | — |
| 39 | Quiver Bioscience Developer of transformational medicines for neurological disorders 67Talent top 28%Funding top 31%AI top 35%Market top 50% All 5 signals ▾Talenttop 28% Fundingtop 31% AItop 35% Markettop 50% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $28.9M across 16 rounds · 16 rounds over 8 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $29M | 2 mo ago | Acquired | 48 | Paul Roma Co-Founder | — | — | — |
| 40 | OncoSynergy Developer of resistance mechanism inhibitors to treat cancer 11Funding top 28%Moat top 32%Patents bottom 48%Global bottom 42% All 6 signals ▾Fundingtop 28% Moattop 32% Patentsbottom 48% Globalbottom 42% Innovationbottom 33% Marketbottom 18% Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $27M | 1 mo ago | Acquired | 3 | — | — | 26 patents Patents concentrated in chemistry & materials | — |
| 41 | Enveric Developer of small-molecule therapeutics for the treatment of neuropsychiatric disorders 42Funding top 29%News top 30%Growth top 31%Talent bottom 49% All 9 signals ▾Fundingtop 29% Newstop 30% Growthtop 31% Talentbottom 49% Fin. healthbottom 42% Techbottom 38% Globalbottom 38% Marketbottom 36% Moatbottom 36% Funding: Raised $26.4M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) News: 15 BI events in 12 mo (of 35 tracked, 3 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 42/100 | $26M | 2 mo ago | Public | 25 | Joseph Tucker CEO | 15 signals ▲200% Earnings · Funding | — | — |
| 42 | CNS Pharmaceuticals Developer of treatments for primary and metastatic cancers in the brain and central nervous system 42Funding top 23%News top 23%Growth top 25%Talent top 43% All 7 signals ▾Fundingtop 23% Newstop 23% Growthtop 25% Talenttop 43% Techbottom 45% Globalbottom 43% Marketbottom 19% Funding: Raised $22.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 6 BI events in 12 mo (of 33 tracked, 7 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 42/100 | $23M | 1 mo ago | Public | 5 | John Climaco CEO | 6 signals ▲200% Leadership · Funding | — | 1 job opening |
| 43 | NeOnc Technologies Holdings Developer of a novel drug delivery platform for CNS diseases 53Funding top 30%Growth top 35%Innovation top 37%Talent top 38% All 8 signals ▾Fundingtop 30% Growthtop 35% Innovationtop 37% Talenttop 38% Techtop 42% Patentstop 42% Globalbottom 42% Marketbottom 25% Funding: Raised $22.3M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $22M | 4 mo ago | Series B | — | Thomas Chen Founder & Co-CEO | — | 48 patents Monoterpene-derived anticancer drugs, especially perillyl alcohol formulations for cancer therapy. | — |
| 44 | Aneuvo Developer of a medical device for the treatment of spinal cord injuries 32Growth top 35%Funding top 39%Tech top 49%Talent bottom 49% All 6 signals ▾Growthtop 35% Fundingtop 39% Techtop 49% Talentbottom 49% Marketbottom 25% Globalbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $22.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $22M | 3 mo ago | Series C | — | Yi Lo CEO | — | — | — |
| 45 | Oryon Developer of autologous neuron replacement medicines for neurodegenerative disorders 50Talent top 28%Funding top 45%Innovation top 49%Patents top 49% All 5 signals ▾Talenttop 28% Fundingtop 45% Innovationtop 49% Patentstop 49% Globalbottom 42% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $21.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $21M | 2 mo ago | Series A | — | Ole Isacson Co-Founder | — | 20 patents Electroluminescent lighting and flexible EL display technologies with nano‑engineered phosphor layers | — |
| 46 | Violet Therapeutics Developer of small molecule therapeutics targeting neurodegenerative diseases of the CNS 48Talent top 38%Funding top 39%Global bottom 48% All 3 signals ▾Talenttop 38% Fundingtop 39% Globalbottom 48% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $15.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $15M | 1 mo ago | Seed | — | Francisco Quintana Co-Founder | — | — | — |
| 47 | Lighthouse Pharma Developer of therapeutics for neurology and infectious diseases 11Funding top 46%Talent bottom 49%Tech bottom 45%Global bottom 25% All 5 signals ▾Fundingtop 46% Talentbottom 49% Techbottom 45% Globalbottom 25% Marketbottom 18% Funding: Raised $15.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $15M | 1 mo ago | Series A | 4 | Casey Lynch Chief Executive Officer | — | — | 1 job opening |
| 48 | Novoron Bioscience Developer of therapeutics for neurological diseases 22Funding top 34%Innovation top 38%Product top 48%Global bottom 32% All 6 signals ▾Fundingtop 34% Innovationtop 38% Producttop 48% Globalbottom 32% Marketbottom 25% Techbottom 24% Funding: Raised $15.1M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Innovation: 3 product lines rank vs industry peers · Fliar Intelligence Index 22/100 | $15M | 3 mo ago | Seed | 11 11 → 16 (+45%) · sector median +71% | — | — | — | 1 job opening · 1 partnership |
| 49 | MindImmune Therapeutics Developing immunotherapeutics to restore neural connections in neurodegenerative diseases 14Talent top 28%Funding top 33%Moat top 48%Global bottom 32% All 6 signals ▾Talenttop 28% Fundingtop 33% Moattop 48% Globalbottom 32% Techbottom 23% Marketbottom 19% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $13.7M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 14/100 | $14M | 3 mo ago | Series A | 7 | Bob Nelson Co-Founder & Vice President of Biology | — | — | 1 expansion |
| 50 | Remedium Bio Developer of gene therapies for a broad range of diseases 7Funding top 37%Moat top 48%Global bottom 36%Tech bottom 22% All 5 signals ▾Fundingtop 37% Moattop 48% Globalbottom 36% Techbottom 22% Marketbottom 20% Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 7/100 | $6M | 1 mo ago | Series A | 5 | — | — | — | 1 job opening |
Top 12 Neurology companies in United States
#1
Series E · Fremont, California · founded 2016 · 197 employees$680Mraised▾
Series E · Fremont, California · founded 2016 · 197 employees
Provider of implantable brain-computer interfaces. It offers flagship product the N1 Implant the Link which is a coin-sized device designed to decode neural signals and enable users to control digital devices using only their thoughts. It also has an experimental device called Blindsight to restore vision in individuals with optic nerve damage by directly stimulating the visual cortex.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Funding
top 15%Patents
top 25%Moat
top 25%Innovation
top 27%Talent
top 28%Market
top 33%Funding: Raised $680M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) · Last round Series E (May 2026)
Patents: 97 patents matched (strict assignee match) · 62 filings since 2022 vs 35 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 9/10 · IP moat: 97 patents · Unicorn
Audience (LinkedIn): 414k LinkedIn followers — 47.2% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2026Series E—
- May 2025Series E$650M
- Nov 2023Series D$43M
- Aug 2023Series D$323.2M
Founders & team
Investors
Founders Fund, Advaita Capital, Setcoin Group, MarketX, Ipo Club, Type One Ventures
Tech stack
Amazon AlbAmazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesApple Icloud Mail
#2
Public · Seattle, Washington · founded 1991 · 25 employees$263.6Mraised▾
Public · Seattle, Washington · founded 1991 · 25 employees
Developer of plant-based alkaloid for treating smoking cessation. The company is developing Cytisinicline, which is a plant-based alkaloid with a binding affinity to the α4β2 nicotine receptor. The candidate is expected to block nicotine cravings and reduce the severity of nicotine withdrawal symptoms.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 11%News
top 42%Moat
top 48%Tech
top 50%Global
bottom 44%Market
bottom 40%Funding: Raised $264M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Post IPO (Apr 2026)
News: 9 BI events in 12 mo (of 54 tracked, 8 types) · -53% YoY · Top themes: Leadership, Earnings
Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Apr 2026Post IPO$180M
- Feb 2024Post IPO$60M
- Nov 2022Post IPO$18.9M
- Aug 2021Grant (prize money)$2.8M
Investors
Propel Bio Partners, Nantahala Capital Management, Sopharma Group, HHS, Frazier Life Sciences, TPG
Tech stack
Apache Http ServerBootstrapCdnjsCloudflareCloudflare Bot ManagementGoogle Tag Manager
#3
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees$207.8Mraised▾
Series C · Cambridge, Massachusetts · founded 2017 · 13 employees
Developer of small molecule-based therapeutics for the treatment of obstructive sleep apnea. The company has developed a combination of Atomoxetine and Oxybutynin which reduces the obstructive sleep apnea severity. It targets the neurological control and activation of upper airway dilator muscles which improve respiration and oxygenation during sleep.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 14%Growth
top 28%Talent
top 28%Moat
top 35%Product
top 40%Tech
bottom 49%Funding: Raised $208M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Conventional Debt (Apr 2026)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Talent: Analyst team rating 5/5 · 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 22k LinkedIn followers — 2.5% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Regional Director, Field Medical Affairs
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Conventional Debt$50M
- Mar 2026Series C$25M
- Sep 2025Conventional Debt$35M
- Apr 2025Series C$16.5M
Founders & team
Investors
Tao Capital Partners, Morningside, Alpha Wave Global, Sectoral, Columbia-Seligman Investments, NexPoint
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsDocusign
#4
Series D · Stanford, California · founded 2013 · 50 employees$157.1Mraised▾
Series D · Stanford, California · founded 2013 · 50 employees
Developer of a wearable non-invasive neuromodulation device. The company has developed a neuromodulation device that aims to provide relief of hand tremors in adults with essential tremors. It combines a watch-like device with an implantable sensor that externally stimulates peripheral nerves to reduce the same. The company has also developed a portable medical device with sensors to monitor the physical movement of a patient wearing or carrying the device.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 17%Product
top 21%Innovation
top 22%Patents
top 26%Moat
top 26%Talent
top 38%Funding: Raised $157M across 7 rounds · 7 rounds over 13 yrs (0.5/yr) · Last round Conventional Debt (Apr 2026)
Product: 6 distinct product lines · Company stage: Series D
Innovation: 243 patents (top 5% of patent-holders) · 127 filings since 2022 vs 106 in 2017-21 · 6 product lines
Audience (LinkedIn): 16k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Conventional Debt$50M
- Oct 2025Series D$50M
- Dec 2024Series D$50M
- May 2022Series D—
Founders & team
Investors
Google Ventures, Novartis, Johnson & Johnson Innovation, Baird Capital, Lux Capital, Lightstone Ventures
Tech stack
AccessibeAmplitudeApple Icloud MailCdnjsChoicesCloudflare
#5
Series E · Plymouth, Minnesota · founded 1999 · 100 employees$174.3Mraised▾
Series E · Plymouth, Minnesota · founded 1999 · 100 employees
Monteris Medical is focused on providing innovative MRI-guided neurosurgical ablation tools and solutions for neurosurgeons. By combining the imaging power of Magnetic Resonance Imaging (MRI), advanced navigation software and Laser Interstitial Thermal Therapy (LITT), Monteris Medical has created a system to reach virtually any area of the brain.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 15%Moat
top 31%Talent
top 38%Market
top 43%Growth
top 48%News
bottom 42%Funding: Raised $174M across 20 rounds · 20 rounds over 18 yrs (1.1/yr) · Last round Conventional Debt (Mar 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 15k LinkedIn followers
Funding rounds
- Mar 2026Series E$28M
- Mar 2026Conventional Debt$35M
- Oct 2022Conventional Debt$38M
- Oct 2022Series D$35M
Founders & team
Investors
BDC, The Vertical Group, Oxford Finance, Madryn Asset Management, InnovaHealth Partners, Birchview Capital
Tech stack
WordpressMysqlPhpContact Form 7Yoast SeoSite Kit
#6
Series C · Cambridge, Massachusetts · founded 2016 · 42 employees$227Mraised▾
Series C · Cambridge, Massachusetts · founded 2016 · 42 employees
Developer of a medical device for the treatment of Alzheimer's disease. The device uses gamma stimulation which helps in reactivating the immune system of the brain. It results in the reduction of amyloid plaques and tau tangles which are typical hallmarks of the disease.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Talent
top 22%Funding
top 23%Growth
top 35%Moat
top 42%Tech
top 50%Market
bottom 43%Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $227M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Series C (Mar 2026)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 15k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. Ochsner Health) announced in 12 mo
Funding rounds
- Mar 2026Series C$105M
- Mar 2025Series C$196.3M
- Jun 2024Series B$10.2M
- Jun 2022Series B$108.8M
Founders & team
Investors
Morningside, FoundersX Ventures, Alzheimer's Drug Discovery, LIfT Biosciences, IAG Capital Partners, WS Investment Company
Tech stack
CdnjsCloudflareCraft CmsFacebook PixelGoogle AnalyticsGoogle Tag Manager
#7
Public · San Francisco, California · founded 2019 · 34 employees$144.7Mraised▾
Public · San Francisco, California · founded 2019 · 34 employees
AI-driven drug discovery platform for neurological diseases based on patients biomarkers. The company's platform measures patients biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to develop personalized psychiatric drugs. The company has pipeline of drugs including ALTO-100 for depression, ALTO-101 for neurodegenerative diseases, and more.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 12%Patents
top 25%Growth
top 30%Moat
top 32%Innovation
top 33%Tech
top 45%Funding: Raised $145M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Post IPO (Mar 2026)
Patents: 57 patents matched (strict assignee match) · 57 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Growth: Headcount 12 → 34 (+183%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 25k LinkedIn followers — 2.8% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Mar 2026Post IPO$120M
- Oct 2025Post IPO$50M
- Nov 2023Series C$45M
- Jan 2023Venture Debt—
Founders & team
Investors
Lightswitch Capital, Novartis, Sobrato, Alkeon Capital Management, Windham Venture Partners, What If Ventures
Tech stack
Apple Icloud MailAstraBugherdCloudflareCore-JsElementor
#8
Public · Bloomington, Minnesota · founded 2010 · 327 employees$400Mraised▾
Public · Bloomington, Minnesota · founded 2010 · 327 employees
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment. It offers a system that measures and records neural activation characteristics. The system quantifies stimulation levels to a clinician-defined target, continuously comparing neural activation with the target level. It automatically adjusts stimulation current to ensure consistent neural activation. The company focuses on neuromodulation solutions for chronic pain. It utilizes Evoked Compound Action Potentials to advance neuromodulation therapy.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 14%Moat
top 31%News
top 39%Growth
top 42%Market
top 44%Tech
top 45%Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) · Last round Series F (Oct 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
News: 3 BI events in 12 mo (of 22 tracked, 4 types) · +50% YoY · Top themes: IPO
Audience (LinkedIn): 34k LinkedIn followers — 3.9% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Oct 2025Series F$30M
- Jan 2025Series F$100M
- Apr 2023Series F$150M
- Mar 2022Series F$125M
Founders & team
Investors
Medtronic, Boston Scientific, Redmile Group, Action Potential Venture Capital, BioScience Managers, NSW Health
Tech stack
Apple Icloud MailAutoptimizeAzureCloudflareCloudflare Bot ManagementCookieyes
#9
Series B · New York City, New York · founded 2019 · 2 employees$83.1Mraised▾
Series B · New York City, New York · founded 2019 · 2 employees
Developer of drugs for neuropsychiatric conditions. The company has an AI-powered discovery and translational platform to develop novel psychotropic drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Products include GM-1020 and GM-2505 an oral NMDAR Antagonist.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Growth
top 15%Funding
top 17%Talent
top 23%News
top 28%Moat
top 39%AI
top 45%Growth: Fresh capital in last 24 mo
Funding: Raised $83.1M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) · Last round Series B (Mar 2026)
Talent: 5 named leaders on record · 5 C-suite/founder profiles curated
Audience (LinkedIn): 11k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: CMC - Drug Substance professional
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. AbbVie) announced in 12 mo
Funding rounds
- Mar 2026Series B$2.2M
- Mar 2026Series B$60M
- Jan 2026Series B$6.1M
- May 2025Grant (prize money)$5.4M
Founders & team
Investors
Prime Movers Lab, Noetic Psychedelic Fund, Gron Ventures, Route 66 Ventures, JLS Fund, Palo Santo
Tech stack
CloudflareGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3
#10
Public · New York City, New York · founded 2015$130.1Mraised▾
Public · New York City, New York · founded 2015
Developer of small molecule based therapeutics for schizophrenia. The company's lead product candidate LB-102, also known as N-methyl amisulpride, is very similar to the marketed antipsychotic amisulpride and differs by only one methyl group (CH3). The drug acts as an antagonist to dopamine (D2, D3), and 5-HT7 receptors and exerts the antipsychotic effect.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Moat
top 21%Growth
top 23%Patents
top 25%News
top 27%Funding
top 30%Innovation
top 34%Moat: Editorial + unicorn rating 7/10 · IP moat: 437 patents
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Patents: 437 patents matched (strict assignee match) · 172 filings since 2022 vs 251 in 2017-21 · Latest publication 2026
Funding rounds
- Feb 2026Post IPO$100M
- Aug 2023Series C$110.7M
- Aug 2020Series B$10M
- Mar 2019Series A$1.6M
Founders & team
Investors
Tarnagulla Ventures
#11
Public · Cambridge, Massachusetts · founded 2014 · 101 employees$92.5Mraised▾
Public · Cambridge, Massachusetts · founded 2014 · 101 employees
Developer of gene therapy platform for Duchenne muscular dystrophy. The lead candidate SGT-001 is Microdystrophin, a synthetic version of the dystrophin gene which stabilizes the muscle membrane and dystrophin-glycoprotein complex. Also, developed a soft wearable device for mobility and help preserve muscle function.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Patents
top 20%Funding
top 24%Innovation
top 31%Tech
top 33%Moat
top 38%News
top 48%Patents: 60 patents matched (strict assignee match) · 43 filings since 2022 vs 17 in 2017-21 · Latest publication 2026
Funding: Raised $92.5M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Innovation: 60 patents (top 27% of patent-holders) · 43 filings since 2022 vs 17 in 2017-21
Funding rounds
- Mar 2026Post IPO$240M
- Jan 2024Post IPO$108.9M
- Dec 2020Post IPO$90M
- Oct 2020Post IPO$40M
Investors
RA Capital Management, RTW Investments, Foresite Capital, Perceptive Advisors, Janus Henderson Investors, Biogen
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#12
Seed · San Francisco, California · founded 2025$250Mraised▾
Seed · San Francisco, California · founded 2025
Developer of brain-computer interfaces to maximize human ability, agency, experience. It focuses on creating new approaches to interact with the brain. The aim is to develop high-bandwidth brain-computer interfaces. These interfaces integrate with advanced artificial intelligence. The goal is to make the technology safe and accessible. The company seeks to restore lost abilities and support healthier brain states. It also aims to deepen connections and expand creative potential.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Talent
top 28%Funding
top 31%AI
top 45%Patents
top 49%Innovation
bottom 49%Tech
bottom 45%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $250M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2026)
AI: Product described with: artificial intelligence
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Jan 2026Seed$250M
Founders & team
Investors
OpenAI
Tech stack
Apple Icloud MailGodaddyGoogle WorkspaceHstsNext.JsNext.Js App Router
Funding & investor landscape
$38.7Btotal disclosed funding
984companies funded
3,640disclosed rounds
18rounds last 90 days
Most active investors
Notable founders
Dongjin Seo
Co-Founder · Neuralink
Elon Musk
Co-Foudner & CEO & Owner · Neuralink
Andrew Wellman
Co-Founder · Apnimed
Lawrence Miller
Co-Founder · Apnimed
Deanna Harshbarger
CEO · Cala Health
Kate Rosenbluth
Founder and Co-President · Cala Health
Richard Tyc
Co-Founder & SVP Science & Technology · Monteris
James Duncan
Co-CEO · Monteris
Ed Boyden
Co-Founder · Cognito Therapeutics
Li-Huei Tsai
Co-Founder · Cognito Therapeutics
Amit Etkin
Founder & CEO · Alto Neuroscience
Jim Schuermann
CEO · Saluda Medical
Prism market signals · United States · country-scoped Prism corpus, 672,586 docs
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
RESEARCH SIGNALS · United States
How research on Neuroscience & Neurotech is moving in the United States
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,477 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 28% → 43% across 2008–2026.
top research entities
- Neurological Surgery622
- Harvard University448
- University of Florida313
- University of California, San Francisco267
- Emory University266
leading researchers
Michael S. Okun · Kelly D. Foote · Philip A. Starr · Cameron C. McIntyre · Jill L. Ostrem · Joshua K. Wong · Andrés M. Lozano · Sameer A. Sheth
▲
Breakthroughs1,435 · 17%
▲ 14%→19% share
▲1.4× share momentum5 median citations51% since 2021mostly methods-led
Neuromodulation research is surging — U.S. breakthrough-segment papers nearly quadrupled (38->144) as field-share climbed to 19%.
rising sub-themes (early→recent)
- Deep brain stimulation180→297
- Neuromodulation38→144
- Stimulation97→176
- Brain stimulation19→78
- Neurostimulation54→105
Newly emergingBrain mapping 0→8 · Biomarker 0→7 · Convolutional neural network 0→7
Landmark Phenomenology and classification of dystonia: A consensus update · 2,210 cites
◆
Advancements4,187 · 49%
▲ 48%→51% share
▲1.1× share momentum8 median citations47% since 2021mostly empirical
Epilepsy advancement research is intensifying — U.S. institutional papers tripled (60->211) within the field's dominant 51% segment.
rising sub-themes (early→recent)
- Deep brain stimulation859→1079
- Neuromodulation95→285
- Neurostimulation157→315
- Stimulation383→535
- Epilepsy60→211
Newly emergingDorsal root ganglion 0→9 · Cochrane Library 0→7 · Entrainment (biomusicology) 0→7
Landmark Neural Stimulation and Recording Electrodes · 2,184 cites
▼
Concerns1,680 · 20%
▼ 22%→18% share
▼0.8× share momentum10 median citations42% since 2021mostly empirical
Chronic pain neurotech concerns are escalating — U.S. concern-segment papers jumped nearly eightfold (3->23), with spinal cord stimulator newly flagged.
rising sub-themes (early→recent)
- Neurostimulation45→123
- Neuromodulation41→110
- Epilepsy21→60
- Transcranial magnetic stimulation17→38
- Chronic pain3→23
Newly emergingArtifact (error) 0→10 · Spinal cord stimulator 0→9 · Meta-analysis 0→8
Landmark A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease · 807 cites
RESEARCH HOTSPOTS · United States
Where neurotech is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston722 · +0.44
SF Bay Area572 · +0.43
New York501 · +0.38
Atlanta304 · +0.34
Pittsburgh282 · +0.50
Chicago268 · +0.35
Seattle262 · +0.48
Los Angeles260 · +0.42
Philadelphia220 · +0.42
Ann Arbor134 · +0.40
PATENT SIGNAL · United States
Who's filing neurotech patents in the United States
United States neurotech patent filing is accelerating — 2,059 filings from 781 assignees (2016–2025), led by Boston Scient Neuromodulation, Medtronic, Advanced Neuromodulation Systems; annual filings 205→349.
2,059 filings781 assigneespeak 349/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Boston Scient Neuromodulation867
- Medtronic277
- Advanced Neuromodulation Systems124
- Cardiac Pacemakers76
- Pacesetter67
- Cyberonics54
- Axonics43
- PREC Neuroscience43
Common questions
How many Neurology companies are there in United States?
Radar tracks 1624 indexable Neurology companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Neurology companies in United States?
The Neurology companies in United States on this list have raised a combined $38.7B in disclosed equity funding across 984 funded companies.
Which is the highest-funded Neurology company in United States?
Assertio is the highest-funded Neurology company in United States, with $906.3M in disclosed equity funding.
How many Neurology companies in United States are funded?
984 of the 1624 Neurology companies in United States on this list have disclosed at least one equity funding round.
How many Neurology unicorns are there in United States?
6 Neurology companies in United States on this list are valued at $1B or more.
Who are the top investors in United States Neurology companies?
The most active investors in United States Neurology companies on this list include HHS, NIH, Orbimed, The Michael J. Fox Foundation, National Science Foundation.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.